Summary
At present the most used method to quantify tumor angiogenesis in human solid tumors is the count of intratumoral microvessels in the primary lesion. This method requires the use of specific markers to vascular endothelium and of immunohistochemical procedures to visualize microvessels. Several studies have found that intratumoral microvessel density (IMD) determined in the primary tumor is significantly associated with metastasis and prognosis in some solid neoplasia, particularly in operable breast carcinoma.
The subjective evaluation of IMD made by two observers at the microscope is rapid and of low cost, but presents some difficulties, mainly the identification of the most vascularized area (“hot-spot”) within each tumor. This method can be improved upon to attain a better reproducibility among different pathologists. For example, the use of a multiparametric computerized image analysis system (CIAS) seems to be a promising tool to improve accuracy, feasibility and reproducibility of microvessel counts, although there are still some open technical problems to completely automate its use.
Angiogenic activity is the result of a balance between angiogenic stimuli and angio-inhibition. Therefore the determination of angiogenic peptides and/or natural angiogenesis inhibitors in the tumor tissue, serum, or urine of cancer patients seems to be a promising alternative to microvessel counting. At present it is possible to determine the expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor, and transforming growth factor beta using immunohistochemical methods. Serum and urine levels of bFGF can be assessed using an immunoenzymatic assay. Methods used to assess the expression and levels of urokinase-type plasminogen activator (uPA) or plasminogen activator inhibitor-1 (PAI-1) have also been developed, and correlate with angiogenic activity and prognosis of patients with breast cancer.
Finally, some investigational methods to assess angiogenesisin vivo are presented and discussed.
Angiogenesis is a very complex phenomenon. Thus it seems reasonable to hypothesize that its assessment by using concurrently several of the available methods may provide more valid, accurate, and comprehensive information on the angiogenic activity of each single tumor. For a reliable and reproducible assessment of angiogenesis for all of the assays, validation procedures and quality control protocols are mandatory.
Similar content being viewed by others
References
Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58–61, 1989.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6, 1990.
Gasparini G: Quantification of intratumoral vascularisation predicts metastasis in human invasive solid tumours [review]. Oncology Rep 1:7–12, 1994.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992.
Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. New Engl J Med 324:1–8, 1991.
Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:458–466, 1994.
Horak E, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastases and survival in breast cancer. Lancet 340:1120–1124, 1993.
Toi M, Kashaitani J, Tominaga T: Tumour angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371–374, 1993.
Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL: Tumor angiogenesis in node negative breast carcinomas — relationship with epidermal growth factor, estrogen receptor, and survival. Breast Cancer Res Treat 29: 109–116, 1994.
Barbareschi M, Weidner N, Gasparini G, Morelli L, Forti S, Eccher C, Fina P, Leonardi E, Mauri MF, Bevilacqua P, Dalla Palma P: Microvessel density quantification in breast carcinomas: a comparison between human counts and computer assisted image analysis. Appl Immunohistochem 3:75–84, 1995.
Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma. Much more than a new prognostic tool [review]. J Clin Oncol 13:765–782, 1995.
Visscher DW, Smilanetz S, Drozdowicz S, Wykes SM: Prognostic significance of image morphometric microvessel enumeration in breast cancer. Anal Quant Cytol Histol 15:88–92, 1993.
Simpson JF, Ann C, Battifora H, Esteban JN: Vascular surface area as a prognostic indicator in invasive breast carcinoma [abstract]. Modern Pathol 7:22a, 1994.
Guinebretiere JM, Le Monique G, Gavoille A, Bahi J, Contesso G: Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 86:635–636, 1994.
Srivastava A, Laidler P, Davies RP, Horgan K, Huges LE: The prognostic significance of tumor vascularity in intermediate thickness (0.76–4.0 mm thick) skin melanoma. Am J Pathol 133: 419–423, 1988.
Srivastava A, Laidler P, Huges LE, Woodcock J, Shedden E: Neovascularization in human cutaneous melanoma: a quantitative morphological and doppler ultrasound study. Eur J Cancer Clin Oncol 22:1205–1209, 1986.
Smolle J, Soyer HP, Hoffmann-Wallenhof R, Smolle-Juettner FM, Kerl H: Vascular architecture of melanocytic skin tumors: a quantitative immunohistochemical study using automated image analysis. Path Res Pract 185:740–745, 1989.
Barnhill RL, Fandrey K, Levy MA, Mihm M, Hyman B: Angiogenesis and tumor progression of melanoma: quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 67:331–337, 1992.
Wakui S, Furusato M, Itoh T, Sasaki H, Akyama A, Kinoshita I, Tokuda T, Aizawa S, Ushigome S: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168:257–262, 1992.
Bigler S, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220–226, 1993.
Paku S, Lapis K: Morphologic aspects of angiogenesis in experimental liver metastases. Am J Pathol 143: 926–936, 1993.
Forti S, Eccher C, Mauri MF, Barbareschi M, Antolini R, Dalla Palma P: Automatic quantification of immunohistochemically detected nuclear antigens using a colorimetric image analysis. Submitted.
Barbareschi M, Girlando S, Mauri MF, Forti S, Eccher C, Mauri FA, Dalla Palma P, Doglioni C: Growth fraction estimates with Ki67 and MIB1 monoclonal antibodies in breast carcinomas. Am J Clin Pathol 102:171–175, 1994.
Folkman J: Angiogenesis and breast cancer [editorial]. J Clin Oncol 12:441–443, 1994.
Gomm JJ, Smith J, Ryall GK, Baillic R, Turnbull L, Coombes RC: Localization of basic fibroblast growth factor and transforming growth factor β1 in the human mammary gland. Cancer Res 51:4685–4692, 1991.
Nanus DM, Schmitz-Drager BJ, Motzer RJ, Lee AC, Vlamis V, Cordon-Cardo C, Albino AC, Reuter VE: Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J Natl Cancer Inst 85:1597–1599, 1993.
Reed JA, McNutt NS, Albino AP: Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated byin situ hybridization. Am J Pathol 144:329–336, 1994.
Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85:1045–1049, 1994.
Liotta LA, Thorgeirsson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1:277–288, 1982.
Bacharach E, Itin A, Keshet E:In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in upregulating physiological angiogenesis. Proc Natl Acad Sci USA 89:10686–10690, 1992.
Bianchi E, Cohen RL, Thor AT, Todd RF III, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54:861–866, 1994.
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR: Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348–1349, 1988.
Grondahl-Hansen J, Christensen IJ, Rasenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosol extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513–2521, 1993.
Janicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Thromb Hemostasis 17:303–332, 1991.
Foekens JA, Schmitt M, van Putten LJ, Peters HA, Kramer MD, Janicke F, Klijn JGM: Plasminogen activator inhibitor -1 and prognosis in primary breast cancer. J Clin Oncol 12:1648–1658, 1994.
Watanabe H, Hori A, Seno M, Kozai Y, Igarashi K, Ichimori Y, Kondo K: A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 175:229–235, 1991.
Fujimoto K, Ichimori Y, Kakizoe T: Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Commun 180: 386–392, 1991.
Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85:241–242, 1993.
Nguyen M, Watanabe, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86:356–361, 1994.
Li V, Yu C, Rupnick M, Allred E, Sallan S, Hayes DF, Folkman J: Serum from breast cancer patients contains proliferative activity for capillary endothelial cells which correlates with risk of mortality [abstract #252]. Proc Am Soc Clin Oncol 12:113, 1993.
Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S-I: Angiogenic activity of enzymes. Nature 368:198, 1994.
Burrows FJ, Tazzari PL, Amlot P, Gazdar AF, Derbyshire EJ, King SW, Letarte M, Vitetta ES, Thorpe PE: Endoglin is an endothelial cell proliferation marker that is upregulated in tumor vasculature. Cancer Res, in press, 1995.
Philip PA, Thompson CH, Carmichael J: A phase-I study of the left-shifting agent bw12c79 plus mitomycin-c and the effect on the skeletal-muscle metabolism using31P magnetic-resonance spectroscopy. Cancer Res 53:5649–5653, 1993.
Torres Filho IP, Leunig M, Yuan F, Intaglietta M, Jain RK: Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci USA 91:2081–2085, 1994.
Fox SB, Gatter KC, Bicknell R,Going JJ, Stanton P, Cooke TG, Harris AL: Relationship of endothelial-cell proliferation to tumor vascularity in human breast cancer. Cancer Res 53:4161–4163, 1993.
Brien SE, Zagzag D, Brem S: Rapidin situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine. Neurosurgery 25:715–719, 1989.
Brem SS, Cotran R, Folkman J: Tumor angiogenesis: A quantitative method for histologic grading. J Natl Cancer Inst 48:347–356, 1972.
Brem SS, Jensen HM, Gullino PM: Angiogenesis as a marker of preneoplastic lesions in human breast. Cancer 41:239–244, 1978.
Wang JM, Kumar S, Pye D, Van Agthoven AJ, Krupinsky J, Hunter RD: A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissue. Int J Cancer 54:363–370, 1993.
Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients [review]. J Natl Cancer Inst 85:1206–1219, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barbareschi, M., Gasparini, G., Morelli, L. et al. Novel methods for the determination of the angiogenic activity of human tumors. Breast Cancer Res Tr 36, 181–192 (1995). https://doi.org/10.1007/BF00666039
Issue Date:
DOI: https://doi.org/10.1007/BF00666039